<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04391062</url>
  </required_header>
  <id_info>
    <org_study_id>2018_58</org_study_id>
    <secondary_id>2019-004796-40</secondary_id>
    <secondary_id>2019-A03157-50</secondary_id>
    <nct_id>NCT04391062</nct_id>
  </id_info>
  <brief_title>Dose Finding for Intraoperative Photodynamic Therapy of Glioblastoma</brief_title>
  <acronym>DOSINDYGO</acronym>
  <official_title>A Multi-center Phase II Study With Light Dose Escalation During Intraoperative Photodynamic Therapy of Glioblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The phase II study evaluate a light dose escalation in a classical intraoperative PDT regimen
      mediated by 5-ALA-PpIX, in glioblastoma patients with access to full surgical removal of the
      contrast enhancement. This treatment will be performed in addition to the current reference
      treatment of glioblastoma: maximum removal surgery followed by radiochemotherapy according to
      the Stupp protocol.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose-Light Level (MTDL) defined as the light dose associated with an acceptable dose-limiting toxicity level (TDL)</measure>
    <time_frame>4 weeks (+/-3 days) post-PDT.</time_frame>
    <description>Dose level above which TDL is observed in more than 33% (i.e., d̀-&gt; 2 of 6) of subjects in an arm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>From the Date of diagnosis of glioblastoma until the date of Relapse, an average 18 months</time_frame>
    <description>Number of patients without relapse within 25 mm of surgical site defined according to International RANO criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Progression Free Survival (PFS)</measure>
    <time_frame>From the Date of diagnosis of glioblastoma until the date of Relapse, an average 18 months</time_frame>
    <description>Median of progression-free survival time determined according to international RANO criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From the Date of diagnosis of glioblastoma until the death, an average 18 months</time_frame>
    <description>Median of OS determined according to international RANO criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to treatment</measure>
    <time_frame>every 3 months between the Date of intraoperative PDT until relapse/death, an average 18 months</time_frame>
    <description>Evaluated by MRI/ TEP 11C-MET every 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of &quot;intraoperative PDT&quot; treatment-emergent Adverse Events</measure>
    <time_frame>From the beginning of treatment with intraoperative PDT up to relapsing/death, an average 18 months</time_frame>
    <description>Collection of all Adverse events (AEs and SAEs) (according to NCI-CTCE V5.0) and reviewing by an Independent Safety Monitoring Board</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Questionnaire -C30 ( QLQ-C30</measure>
    <time_frame>Every 3 months from the signature of Consent form until relapse/death, an average 18 months</time_frame>
    <description>The QLQ-C30 is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, a global health status / QoL scale, and six single items</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Questionnaire - Brain Cancer Module (QLQ-BN20)</measure>
    <time_frame>Every 3 months from the signature of Consent form until relapse/death, an average 18 months</time_frame>
    <description>Measuring the health-related quality of life in patients with brain cancer</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>intraoperative PDT 400J/cm²</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>intraoperative PDT 600J/cm²</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>intraoperative PDT 800J/cm²</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gliolan</intervention_name>
    <description>patient will receive 5-ALA 4 to 6 hours before surgery</description>
    <arm_group_label>intraoperative PDT 400J/cm²</arm_group_label>
    <arm_group_label>intraoperative PDT 600J/cm²</arm_group_label>
    <arm_group_label>intraoperative PDT 800J/cm²</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intraoperative PDT</intervention_name>
    <description>The protocol requires the realization of specific procedures in addition to the usual care.
The intra-operative photodynamic therapy (&quot;intraoperative PDT&quot;) added to surgery for glioblastoma excision. The patient will receive 5-ALA ( 5-aminolevulinic acid hydrochloride),GLIOLAN drinkable 6h before surgery + lighting of the tumor bed by a red light source (laser with different J/cm²) at the end of resection (Prolonged surgery of 45 minutes).</description>
    <arm_group_label>intraoperative PDT 400J/cm²</arm_group_label>
    <arm_group_label>intraoperative PDT 600J/cm²</arm_group_label>
    <arm_group_label>intraoperative PDT 800J/cm²</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  General status (WHO) Karnofsky Performance Status ≥60

          -  Presumptive glioblastoma according to radiological criteria,

          -  Surgical indication decided in Multidisciplinary consultation meeting (RCP) of neuro
             oncology,

          -  Decision to treat the patient as part of the Clinical trial achieved in neuro-oncology
             RCP (&quot;Multidisciplinary consultation meeting&quot;)

          -  Patient operable on the basis of absence of cardiopulmonary disease history; a
             complete medical check-up sufficient to insure a post-operative state with normal
             daily life

          -  Clinical neuro-oncological monitoring and long-term MRI/ TEP 11C MET scheduled at the
             hospital centers

          -  Patient able to understand and sign voluntarily Informed consent

          -  Patient able to adhere to the visit's calendar of the study and other imperatives of
             the protocol

          -  Women of child-bearing potential should benefit of an effective contraception

          -  For patients receiving hepatotoxic therapy in the long term, this treatment must be
             suspended during the 24h after taking 5-ALA

        Exclusion Criteria:

          -  Contraindications to 5-ALA (Gliolan®) and to intra-operative PhotoDynamic Therapy
             &quot;intraoperative PDT&quot;:

          -  Contraindications to 5-ALA

               -  Porphyria

               -  Taking photosensitizer treatment

               -  Severe renal or hepatic impairment

               -  Bilirubin&gt; 1.5 x maximum level, Alkaline Phosphatases and transaminases (ASAT)&gt;
                  2.5 x Maximum. rates

               -  Creatinine clearance &lt;30 mL / min;

               -  Non-compliance with the rules of prevention of the transient risk of cutaneous
                  photosensitization

          -  Contraindications to surgery

          -  Contraindications to magnetic resonance imaging (MRI/TEP 11C MET

          -  Treatment with an experimental drug within 30 Days prior to the start of the study

          -  Clinical follow-up impossible to perform for psychological, familial, social or
             geographical reasons,

          -  Legal incapacity (persons deprived of their liberty or Guardianship or guardianship),

          -  Pregnant or nursing women

          -  Refusal to participate or sign the consent of the study

          -  Soy allergy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas Reyns, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicolas Reyns, MD,PhD</last_name>
    <phone>+33320446721</phone>
    <email>nicolas.reyns@chru-lille.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maximilien Vermandel, MD</last_name>
    <phone>+33320446721</phone>
    <email>maximilien.vermandel@chru-lille.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Erasme, Clinique Universitaire de Bruxelles</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <investigator>
      <last_name>Florence Lefranc, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Roger Salengro, CHU Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <phone>0320445962</phone>
    </contact>
    <investigator>
      <last_name>Nicolas Reyns, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 12, 2020</study_first_submitted>
  <study_first_submitted_qc>May 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2020</study_first_posted>
  <last_update_submitted>May 20, 2020</last_update_submitted>
  <last_update_submitted_qc>May 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Surgical indication of glioblastoma</keyword>
  <keyword>Glioblastoma</keyword>
  <keyword>Photodynamic Therapy</keyword>
  <keyword>Neurosurgery</keyword>
  <keyword>Oncology</keyword>
  <keyword>5-aminolevulinic Acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

